Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT.
Acute Disease
Adolescent
Adult
Aged
Disease Progression
Europe
/ epidemiology
Female
Graft vs Host Disease
/ diagnosis
Health Care Costs
Health Care Surveys
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Incidence
Male
Middle Aged
Mortality
Prognosis
Registries
Retrospective Studies
Risk Assessment
Risk Factors
Severity of Illness Index
Socioeconomic Factors
Transplantation, Homologous
Treatment Outcome
Young Adult
acute graft-vs.-host disease
health care expenditure
hematopoietic cell transplantation
human development index
transplant-related mortality
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
05
2020
accepted:
11
06
2020
entrez:
15
8
2020
pubmed:
15
8
2020
medline:
15
4
2021
Statut:
epublish
Résumé
Acute graft-vs.-host disease (aGvHD) is one of the most frequent causes of transplant-related mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). Its treatment is complex and costly. The aim of this study was to retrospectively analyze the impact of country-specific socioeconomic factors on outcome of patients who experience severe aGvHD. Adults with hematological malignancies receiving alloHCT from either HLA-matched siblings (
Identifiants
pubmed: 32793210
doi: 10.3389/fimmu.2020.01537
pmc: PMC7390847
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1537Informations de copyright
Copyright © 2020 Frankiewicz, Peczynski, Giebel, Harrington, Socié, Niederwieser, Scheid, Bornhäuser, Kröger, Elmaagacli, Afanasyev, Dreger, Rössig, Blaise, Kratz, Yakoub-Agha, Kremens, Niemeyer, Wulf, Blau, Penack, Greinix and Basak.
Références
Biol Blood Marrow Transplant. 2018 Feb;24(2):393-399
pubmed: 29032275
Haematologica. 2017 Jan;102(1):139-149
pubmed: 27686376
Stat Med. 1999 Mar 30;18(6):695-706
pubmed: 10204198
Stat Med. 1999 Jun 30;18(12):1489-500
pubmed: 10398287
Blood. 1998 Oct 1;92(7):2288-93
pubmed: 9746766
Blood. 2011 Mar 17;117(11):3214-9
pubmed: 21263156
Blood. 2010 Jul 8;116(1):122-8
pubmed: 20395416
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Bone Marrow Transplant. 2000 Nov;26(10):1061-7
pubmed: 11108304
Bone Marrow Transplant. 2013 Feb;48(2):238-42
pubmed: 22773125
Curr Opin Immunol. 2009 Oct;21(5):544-8
pubmed: 19766472
Bone Marrow Transplant. 2006 Feb;37(4):419-23
pubmed: 16415897
Blood. 2012 Jan 5;119(1):296-307
pubmed: 22010102
N Engl J Med. 2017 Nov 30;377(22):2167-2179
pubmed: 29171820
Biol Blood Marrow Transplant. 2012 Mar;18(3):406-13
pubmed: 21736868
Blood. 1992 May 15;79(10):2771-4
pubmed: 1586723
Lifetime Data Anal. 1995;1(3):255-73
pubmed: 9385105
JAMA. 2010 Apr 28;303(16):1617-24
pubmed: 20424252
Lancet. 2000 Apr 22;355(9213):1393-8
pubmed: 10791522
Oncologist. 2016 Mar;21(3):377-83
pubmed: 26869584